Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System-Reference-Cited by-同舟云学术

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Published:2017-04-25 Issue:11 Volume:166 Page:792
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Bersoff-Matcha Susan J.¹,Cao Kelly¹,Jason Mihaela¹,Ajao Adebola¹,Jones S. Christopher¹,Meyer Tamra¹,Brinker Allen¹

Affiliation:

1. From U.S. Food and Drug Administration, Silver Spring, Maryland.

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Self‐reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013–2017: A nationwide population‐based study;Journal of Viral Hepatitis;2024-07-30

2. High prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment;Harm Reduction Journal;2024-01-29

3. Hepatitis B virus coinfection in patients treated for chronic hepatitis C: Clinical characteristics, risk of reactivation with long-term follow-up and effectiveness of antiviral therapy;Polish Archives of Internal Medicine;2024-01-02

4. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01

5. Management of HBV reactivation: Challenges and opportunities;Clinical Liver Disease;2024-01